Back to discover

Protein / target

Peptidyl-prolyl cis-trans isomerase F, mitochondrial

Encoded byPPIFP30405Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Peptidyl-prolyl cis-trans isomerase

Strongest disease association

Hair color

Via encoding gene PPIF · Genetic evidence · score 0.26

Research activity

Emerging research

1 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding.

View complete UniProt function annotation

PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding (PubMed:20676357). Involved in regulation of the mitochondrial permeability transition pore (mPTP) (PubMed:26387735). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated (PubMed:26387735). In cooperation with mitochondrial p53/TP53 is involved in activating oxidative stress-induced necrosis (PubMed:22726440). Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels (By similarity). Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis (PubMed:19228691)

Subcellular location

Mitochondrion matrix
Domains and Gene Ontology detail (22)

Domains & features

PPIase cyclophilin-type

Gene Ontology

  • Ccytoplasm
  • Cmembrane
  • Cmitochondrial matrix
  • Cmitochondrial permeability transition pore complex
  • Cmitochondrion
  • Fcyclosporin A binding
  • Fenzyme inhibitor activity
  • Fpeptidyl-prolyl cis-trans isomerase activity
  • Papoptotic process
  • Pcellular response to arsenic-containing substance
  • Pcellular response to calcium ion
  • Pcellular response to hydrogen peroxide

207 aa · 22 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Apoptosis & cell deathGO
View supporting evidence

Apoptosis & cell death

  • ·apoptotic process
  • ·mitochondrial outer membrane permeabilization involved in programmed cell death
  • ·negative regulation of apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene PPIF

Gene-level evidence surfaced through the gene PPIF that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Neurodegenerative Diseases
0.33Preliminary

Pathway evidence dominant · Open Targets 0.50 · no direct causal or clinical evidence

Diabetes Mellitus
0.28Limited support

Genetic evidence dominant · Open Targets 0.14

Hair color
0.26Limited support

Genetic evidence dominant · Open Targets 0.16

Diabetes Mellitus, Type 2
0.25Limited support

Genetic evidence dominant · Open Targets 0.15

Psoriasis
0.21Preliminary

Genetic evidence dominant · Open Targets 0.11

View evidence synthesis (5)
Neurodegenerative DiseasesPreliminary
0.33
agreement 0.160.51
Pathway98%Literature2%

Open Targets aggregate 0.50 · 2 independent evidence families · no direct causal or clinical evidence

Diabetes MellitusLimited support
0.28
agreement 0.140.42
Genetic67%Literature34%

Open Targets aggregate 0.14 · 2 independent evidence families

Hair colorLimited support
0.26
agreement 0.140.38
Genetic100%

Open Targets aggregate 0.16 · 1 independent evidence family

Diabetes Mellitus, Type 2Limited support
0.25
agreement 0.110.39
Genetic92%Literature8%

Open Targets aggregate 0.15 · 2 independent evidence families

PsoriasisPreliminary
0.21
agreement 0.090.34
Genetic76%RNA expression14%Literature11%

Open Targets aggregate 0.11 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.50
Hair color0.16
Diabetes Mellitus, Type 20.15
Diabetes Mellitus0.14
Metabolic Diseases0.11
Hyperlipidemias0.11
Psoriasis0.11

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
SM · Structure with LigandPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.